Skip to main content
Open Access Publications from the University of California

Next Generation Lentiviral Vectors for the Gene Therapy of Hemoglobinopathies

  • Author(s): Morgan, Richard
  • Advisor(s): Kohn, Donald B
  • et al.
No data is associated with this publication.

We set out to improve upon current β-globin expressing lentiviral vectors (LV) designs by rationally reengineering human genomic sequences through the removal and/or addition of known elements. Although this approach generated improved LV designs, it is a low-throughput model for LV development, where large sections of DNA containing roughly-defined elements are simply inserted and/or removed from LVs and tested against a litany of criteria until a combination of well-performing elements are found (typically occurring over a span of years). To speed up LV development, we concurrently developed an advanced LV-engineering technology that can be broadly applied to the design of any gene therapy LV that requires high-level and lineage specific expression. Our Lentiviral Vector based, Massively Parallel Reporter Assay (LV-MPRA) allowed us to map the precise boundaries of lineage specific enhancers within large genomic regions (>16kb). The enhancer maps generated guided the assembly of novel enhancer combinations that when placed in a globin expression LV conferred robust transgene expression within a minimal DNA footprint. While our original “intelligent” design approach generated LV designs with improved performance (when compared to antecedent clinical LVs), vectors designed using the LV-MPRA based enhancer mapping approach possessed similar improvements in performance and were generated in only a fraction of the time (~3 months vs ~3 years). Moreover, LVs generated by either approach corrected the “Townes” mouse model of Sickle Cell Disease. The yields of this research offer improved “next generation” LVs for the gene therapy of hemoglobinopathies.

Main Content

This item is under embargo until July 9, 2021.